NCT01822418View on ClinicalTrials.gov

Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)

PHASE4CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
SchizophreniaSchizoaffective DisorderDelusional Disorder
Interventions
DRUG

agomelatine

Augmentation of antipsychotic therapy with 25 to 50 mg agomelatine as a single oral dosage per day

Trial Locations (1)

68159

Central Institute of Mental Health, Mannheim

All Listed Sponsors
collaborator

Servier

INDUSTRY

lead

Central Institute of Mental Health, Mannheim

OTHER

NCT01822418 - Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH) | Biotech Hunter | Biotech Hunter